We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

50 hedge funds and large institutions have $21.5M invested in Matinas BioPharma in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more capital invested

Capital invested by funds: $20.3M → $21.5M (+$1.21M)

0.02% more ownership

Funds ownership: 0.23% → 0.25% (+0.02%)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

11% less funds holding

Funds holding: 56 → 50 (-6)

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

Holders
50
Holders Change
-6
Holders Change %
-10.71%
% of All Funds
0.84%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
8
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NRS
Neville Rodie & Shaw
New York
+$1.32M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$403K
3
SIG
Sargent Investment Group
Maryland
+$242K
4
Jane Street
Jane Street
New York
+$112K
5
VF
Virtu Financial
New York
+$70.1K

Top Sellers

Rank Fund Capital Flow
1
CCM
Courage Capital Management
Tennessee
-$509K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$60.6K
3
SCP
Sandhill Capital Partners
New York
-$40K
4
JMPWA
JP Morgan Private Wealth Advisors
California
-$26K
5
IWC
Integrated Wealth Concepts
Massachusetts
-$20K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$31K -$9.99K -262 -25%
AWS
27
Atria Wealth Solutions
New York
$31K – – –
DAS
28
Dynamic Advisor Solutions
Arizona
$24K – – –
MA
29
MONECO Advisors
Connecticut
$24K – – –
Osaic Holdings
30
Osaic Holdings
Arizona
$24K – – –
Victory Capital Management
31
Victory Capital Management
Texas
$23K -$76 -2 -0.3%
Commonwealth Equity Services
32
Commonwealth Equity Services
Massachusetts
$23K +$191 +5 +0.9%
Wells Fargo
33
Wells Fargo
California
$16K +$76 +2 +0.5%
RPC
34
Rossmore Private Capital
Connecticut
$14K +$13.3K +350 New
MFG
35
Magnus Financial Group
New York
$12K +$11.4K +300 New
SBWIC
36
Schaper Benz & Wise Investment Counsel
Wisconsin
$11K – – –
CG
37
Clarus Group
Texas
$9K – – –
BJL
38
Brighton Jones LLC
Washington
$8K – – –
CFS
39
CRA Financial Services
New Jersey
$8K – – –
FAIM
40
Financial Advocates Investment Management
Washington
$8K – – –
JWCA
41
J.W. Cole Advisors
Florida
$8K – – –
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$6K -$4.27K -112 -43%
VVP
43
Venture Visionary Partners
Ohio
$3.8K +$3.66K +96 New
Bank of America
44
Bank of America
North Carolina
$3K – – –
HFM
45
Hartford Financial Management
Connecticut
$2K – – –
IA
46
IFP Advisors
Florida
$2K – – –
SPIA
47
Steward Partners Investment Advisory
New York
$2K – – –
GWMIA
48
Global Wealth Management Investment Advisory
Florida
$1K – – –
SCP
49
Sandhill Capital Partners
New York
– -$40K -1,000 Closed
JMPWA
50
JP Morgan Private Wealth Advisors
California
– -$26K -634 Closed
1
2
3

MTNB Hedge Fund Activity: Q2 2022 in Review

50 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2022, worth a combined $21.5M — up 6% from $20.3M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of MTNB and 5 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 8 added.

The largest buyer was Neville Rodie & Shaw, adding an estimated $1.32M. The largest seller was Courage Capital Management, cutting an estimated $509K.

  • 50 institutional investors held Matinas BioPharma (MTNB) as of Q2 2022, down from 56 in Q1 2022.
  • Funds reported $21.5M of Matinas BioPharma stock for Q2 2022, up 6% quarter-over-quarter.
  • 5 funds opened new Matinas BioPharma positions in Q2 2022 and 11 closed out, a net change of -6 holders.
  • The largest Matinas BioPharma buyer in Q2 2022 was Neville Rodie & Shaw, an estimated $1.32M added.
  • The largest Matinas BioPharma seller in Q2 2022 was Courage Capital Management, an estimated $509K sold.

Based on aggregated 13F filings for Q2 2022.